麻豆视频

Market Trends and Insights

Increasing adoption of GLP-1 agonists in obese T2DM

GLP-1 receptor agonists unify obesity and diabetes management, a nexus relevant to more than 88% of people with Type 2 diabetes. Tirzepatide reached roughly 12% prescription share of glucose-lowering drugs by end-2023, and its popularity among non-diabetic weight-management users underscores the therapeutic blur between metabolic indications.^{[2]Jaime Almandoz MD et al., 鈥淒iscussing Tirzepatide鈥檚 Rise in Diabetes, Obesity Care,鈥� ajmc.com} Dual GLP-1/GIP activity delivers greater body-weight and HbA1c reductions than single-target drugs, while emerging triple-agonists such as retatrutide have posted 24% weight loss at 48 weeks, setting new clinical benchmarks. Fast-tracked FDA approvals for wider cardiometabolic indications are expanding reimbursement horizons and encouraging prescribers to adopt these therapies earlier in care pathways.

Reimbursement expansion for dual & triple incretins

Payers are recalibrating formularies to recognize the cardiovascular and renal benefits of dual and triple incretins. Medicare鈥檚 price negotiations apply greater pressure on legacy oral agents, while newer GLP-1s gain Tier-preferred coverage, thus lowering out-of-pocket costs for seniors.^{[3]Medicare Rights Center, 鈥淎dministration Provides More Data on First 10 Drugs Subject to Price Negotiation,鈥� medicarerights.org}Commercial insurers now classify obesity as a medical condition, unlocking pharmacotherapy budgets previously reserved for diabetes. Employer health plans are bundling obesity and diabetes care contracts tied to outcome metrics, reinforcing utilization growth.

Biosimilar insulin price wars accelerate uptake

Since the USD 35 insulin copay cap took effect, biosimilar manufacturers have accelerated market entries and discounting strategies, spurring wider patient adoption and forcing innovators to adjust list prices. Teva鈥檚 capacity expansions under federal purchasing agreements illustrate the corporate commitment to compete on volume. Intensifying price competition is broadening insulin access and enlarging overall therapy volumes.

CGM-linked dosing algorithms spur drug adherence

Integrating semaglutide with real-time continuous glucose monitoring (CGM) has produced an additional 0.55 percentage-point HbA1c reduction versus drug therapy alone. Newer CGM algorithms, though occasionally understating hypoglycemia risk, improve titration accuracy and bolster adherence. Over-the-counter CGM devices now receiving FDA clearance promise to widen technology adoption and reinforce medication persistence.

Payer prior-authorization throttles GLP-1 volumes

US payers continue to impose multi-step therapy rules that delay or deny GLP-1 initiation despite favorable clinical profiles, leading to patient drop-out and slower overall market penetration. Medicare Advantage plans remain especially cautious in approving weight-management uses, preserving utilization caps that curb early growth.

API tariff risk from China supply concentration

Roughly two-thirds of global active pharmaceutical ingredient output for diabetes therapies still originates in China. Any re-imposition of punitive tariffs could elevate input costs and disrupt downstream supply, pressuring North America diabetes drugs market margins until alternative sourcing scales.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

North America Diabetes Drugs Market Segment Analysis

Oral agents secured 67.72% of the North America diabetes drugs market in 2025 and are projected to expand at 4.87% CAGR through 2031, sustaining leadership despite injectable breakthroughs. SGLT-2 inhibitors such as canagliflozin continue to gain based on cardio-renal outcome data and Health Canada labeling updates.

Non-insulin injectables are climbing rapidly on the back of GLP-1, dual GIP/GLP-1, and emerging triple-agonist classes. Triple-mechanism drugs are positioned as premium therapies offering weight, cardiovascular, and renal benefits, thereby lifting value per prescription within the North America diabetes drugs market. Alpha-glucosidase inhibitors retain a niche among geriatric cohorts, and combination pills that merge multiple mechanisms aim to simplify dosing and boost adherence.

Therapies for Type 2 diabetes continue to dominate revenue, yet Type 1 options are showing the strongest incremental gains. Integration of weekly semaglutide with automated insulin delivery lifted time-in-range metrics from 69.4% to 74.2%, a meaningful clinical advance. The resulting enthusiasm is expanding the North America diabetes drugs market size for Type 1 adjuncts. Gene-therapy programs aimed at beta-cell regeneration are still pre-commercial but underscore the pipeline depth.

Branded medications still account for 78.84% of the North America diabetes drugs market share, but the trajectory favors biosimilars. The USD 35 insulin copay cap erodes traditional branding advantages, allowing follow-on manufacturers to compete primarily on availability and service. Federal contract wins and streamlined FDA interchangeability guidelines should accelerate penetration of biosimilar insulin glargine, lispro, and aspart across retail and specialty channels.

Retail pharmacies retained 50.76% share in 2025, yet online channels are scaling at 8.41% CAGR as patients gravitate to subscription refills and home delivery. PBM-owned mail facilities direct a disproportionate volume of high-cost GLP-1 scripts, partially offset by 鈥渁ny willing pharmacy鈥� rules that broaden independent pharmacy participation. The rise of telehealth-linked e-pharmacies is expected to reinforce competition on convenience and copay assistance rather than on sheer geographic presence.

Geography Analysis

United States Diabetes Drugs Market

The United States generated 89.02% of North America diabetes drugs market revenues in 2025, driven by high per-capita healthcare spend and broad insurance coverage. Federal drug-price negotiations could deliver USD 98.5 billion in savings over a decade, with legacy diabetes brands among the first 10 products slated for price ceilings. State price-cap laws introduce patchwork compliance burdens but may spur regional competitive discounts.

Canada Diabetes Drugs Market

Canada鈥檚 market is steered by provincial formularies and rigorous health-technology assessments. While dual-agonist GLP-1s are receiving incremental coverage, uptake varies by province, leaving room for branded manufacturers to demonstrate cost-effectiveness through outcomes evidence. Generic adoption remains comparatively high in Ontario and Qu茅bec, reinforcing pressure on innovators.

Mexico Diabetes Drugs Market

Mexico is the fastest-growing territory, clocking a forecast 6.18% CAGR through 2031. Expansion of COFEPRIS fast-track approvals and US鈥揗exico near-shoring of injectable-pen assembly lines are fortifying supply chains, lowering prices, and enhancing local availability. As manufacturing employment grows near border clusters, domestic insurance penetration is widening, further enlarging the addressable population for modern antidiabetic therapies.

Regulatory Landscape

In North America, diabetes-drug regulation is shaped by the US Food and Drug Administration (FDA), Health Canada, and Mexico's COFEPRIS, with recent actions spanning novel delivery innovation, expanded indications, and faster-moving generic pathways. In March 2026, the FDA approved Novo Nordisk's Awiqli (insulin icodec-abae) as the first once-weekly basal insulin for adults with type 2 diabetes. The agency also continued to broaden treatment coverage to younger populations via pediatric decisions, including a June 2026 action on Tzield for pediatric stage 3 type 1 diabetes, and it signaled active lifecycle management through review designations such as Bayer's Priority Review for a KERENDIA (finerenone) sNDA in May 2026.

Policy and compliance requirements are also affecting access and competitive conduct. In April 2026, the FDA clarified its enforcement posture for 503A and 503B compounders as national GLP-1 supply conditions began stabilizing, tightening the boundary between approved products and compounded alternatives. In Canada, Health Canada moved quickly on GLP-1 competition, authorizing the first generic semaglutide injection in April 2026 and a second generic in May 2026. That sequence creates a distinct pricing and access environment versus the United States. Across the region, payer-side controls described in the market context, including Medicare negotiation pressure and state price-cap statutes in the US, amplify the downstream impact of approvals on formulary placement and net pricing.

Value Chain Analysis

The diabetes-drugs value chain in North America runs from active pharmaceutical ingredient (API) and excipient sourcing through drug-substance production, sterile fill-finish (especially for insulins and GLP-1 class injectables), packaging (vials, cartridges, pens), and then commercialization via wholesalers, PBMs, and dispensing channels (hospital, retail, and online pharmacies). Scale and reliability in sterile manufacturing and device-compatible packaging have become central constraints as non-insulin injectables gain momentum. Oral anti-diabetics continue to support high-volume throughput through more standardized solid-dose operations.

Recent supply-chain moves show a tilt toward capacity build-out and localized partnerships to secure essential insulin availability and mitigate offshore exposure. Eli Lilly announced a USD 3 billion expansion (December 2024) of its Pleasant Prairie, Wisconsin facility to increase capacity for parenteral medicines, including diabetes and obesity therapies. In the US insulin value chain, Biocon Biologics and Civica, Inc. expanded collaboration in October 2025 to include private-label insulin glargine commercialization, and in March 2025 they outlined insulin aspart production at Civica's Petersburg, Virginia plant with Biocon supplying drug substance. This model blends external manufacturing with controlled upstream supply. At the distribution end, PBM-owned mail facilities and rapidly scaling online pharmacies increasingly shape reach and adherence for high-cost GLP-1 prescriptions, shifting competitive emphasis toward contracting, fulfillment reliability, and patient-support services.

Market Opportunities and Future Outlook

Opportunities are opening where regulatory actions, capacity investments, and care-model shifts reduce friction between clinical demand and supply availability. Once-weekly basal insulin entered the US market through the FDA's March 2026 approval of Novo Nordisk's Awiqli (insulin icodec-abae). This creates whitespace for adherence-focused basal insulin switching, contracting strategies around weekly dosing, and combination pathways with CGM-linked titration tools already highlighted in the market context. Pediatric label expansion also broadens treated populations, with Health Canada approving Eli Lilly's Mounjaro (tirzepatide) for children aged 10 years and older with type 2 diabetes in July 2026. That development supports more structured transition programs that connect pediatric endocrinology, family adherence services, and long-term therapy persistence.

A second opportunity track is cost management and access expansion through new sources of competition and expanded regional manufacturing. Health Canada's April 2026 authorization of the first generic semaglutide injection, followed by a second generic authorization in May 2026, provides a concrete pathway for payers and pharmacies to widen GLP-1 access in Canada and pressure net prices via substitution and tendering. On supply resilience for high-demand injectables, manufacturers are committing large capital to North American capacity: Eli Lilly increased investment to a total of USD 9 billion at its Lebanon, Indiana site (May 2024) to boost API production for tirzepatide; Novo Nordisk announced a USD 4.1 billion investment for a second fill-and-finish facility in Clayton, North Carolina (June 2024); and Lilly announced the USD 3 billion Wisconsin expansion (December 2024). These moves align with the report's observed shift toward near-shoring and supply-chain de-risking, and they create room for contract manufacturing, packaging components, and specialty distribution services that can support consistent availability as payer utilization controls continue to redirect demand across brands, biosimilars, and channels.